Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product BusulipoTM, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation , has received orphan drug designation from the US Food and Drug Administration .
http://www.biospace.com/news_story.aspx?StoryID=313456&full=1
http://www.biospace.com/news_story.aspx?StoryID=313456&full=1
No comments:
Post a Comment